Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Saurabh Agrawal

Tata Sons listing: Who holds the shares, who holds the cards

Tata Sons’ board has backed Chandrasekaran for another five years and begun considering steps to meet RBI requirements that could lead to a listing. But Tata Trusts, which owns about 66% of the holding company, is challenging his reappointment and opposes an IPO—setting up a battle between the board, controlling…

The Economic Times

Tata Sons succession race narrows to T V Narendran, Saurabh Agrawal; NSE's Ashish Chauhan emerges as dark horse

Tata Sons has narrowed its search for N Chandrasekaran’s successor to three names: Tata Steel CEO T V Narendran, Tata Sons Group CFO Saurabh Agrawal, and NSE CEO Ashish Chauhan.

The Economic Times

Tata Sons chairman N Chandrasekaran among India's highest-paid executives with Rs 158.66 crore FY26 pay

Tata Sons Executive Chairman N Chandrasekaran earned Rs 158.66 crore in FY26. This represents a slight increase from the previous financial year's earnings. His compensation primarily consists of a substantial profit-linked commission. The Tata Group reported significant revenue and profit growth for FY26. Chief Financial Officer Saurabh Agrawal was the…

The Economic Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Trade disruptions, API dependence, compliance costs: Pharma MSMEs spell out policy priorities on World MSME Day

Indian pharmaceutical MSMEs are facing immense pressure from rising costs, supply chain woes, and stringent regulations. Industry representatives urge policy reforms, including energy access and expanded PLI schemes, to bolster competitiveness. Delayed GST refunds and liquidity issues further challenge smaller drug manufacturers, impacting their ability to compete globally and respond…

The Economic Times

Over 60% of pharma MSMEs yet to comply with updated manufacturing norms

Pharma industry officials say the revised Schedule M regulations could require Rs 10-15 crore per facility in upgrades, while talent shortages, funding constraints, and rising compliance costs pose challenges for smaller drug makers within the SME ecosystem..

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.